Comprehensive approach to a patient with arterial hypertension and dyslipidemia

Česká verzia

Authors: Zdeněk Ramík ^1,2; Jan Václavík ^1,2; Pavla Jadrníčková ¹; Jana Obrová ³; Janula Stromská ¹
Authors place of work: Interní a kardiologická klinika, Fakultní nemocnice Ostrava ¹; Lékařská fakulta Ostravské univerzity ²; I. interní klinika – kardiologická, Fakultní nemocnice Olomouc ³
Published in the journal: Vnitř Lék 2022; 68(6): 376-386
Category: Review Articles
doi: https://doi.org/10.36290/vnl.2022.078

Summary

Arterial hypertension together with dyslipidemia, diabetes and smoking are the most severe risk factors for cardiovascular (CV) disease. The Czech Republic is among the countries with a high risk of cardiovascular disease. To reduce cardiovascular mortality and morbidity in our patients, a comprehensive approach to treatment and, in most cases, aggressive control of all risk factors is needed. This article summarizes current diagnostic and therapeutic procedures for arterial hypertension and dyslipidaemia, as well as the concept of vascular age, which can help us to communicate CV risk with patients.

Keywords:

arterial hypertension – vascular age – dyslipidemia – vascular memory

Zdroje

1. Visseren JLF, Mach F, Smulders MY et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. Volum. 2021;42(34):3227-3337.

2. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111- 188. doi:10.1093/eurheartj/ehz455

3. Táborský M., Vrablík M. Prevence kardiovaskulárních onemocnění. Doporučený diagnostický a terapeutický postup pro všeobecné praktické lékaře 2022.

4. Williams B, Mancia G, Spiering W et. Al. Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), European Heart Journal. 2018;39(33):3021-3104.

5. Vráblík M, Piťha J, Blaha V et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. Hypertenze a KV prevence 2019;2:68-77.

6. Václavík J. Obtížně léčitelná hypertenze. Druhé vydání. Praha: Mladá fronta, 2017. 134 s. ISBN 978-80204-4421-9.

7. Ramík Z., Václavík J. Valsartan: možnosti preskripce v ordinaci praktického lékaře. Acta medicinae 2021;15:56-58.

8. Hatala R, Pella D, Hatalová K et al. Optimization of Blood Pressure Treatment with Fixed‑Combination Perindopril/Amlodipine in Patients with Arterial Hypertension. Clin Drug Investig 2012;32(9):603-612.

9. Wald S et al. Combination therapy versus monotherapy in reducing blood pressure: meta‑analysis on 11,000 participants from 42 trials. Ann. Int. Med. 2009.

10. Parati G et al. Adherence to Single‑Pill Versus Free‑Equivalent Combination Therapy in Hypertension. Hypertension2021;77:692–705.

11. Cuende JI et al. European Heart Journal (2010) 31, 2351–2358. doi:10.1093/eurheartj/ ehq205

12. Gupta A, Mackay J, Whitehouse A et al. Long‑term mortality after blood pressure‑lowering and lipid‑lowering treatment in patients with hypertension in the Anglo‑Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow‑up results of a randomised factorial trial. Lancet. 2018;392(10153):1127-1137. doi:10.1016/S0140- 6736(18)31776-8.

13. Olsen MH, Angell SY, Asma S et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016;388:2665-2712.

14. Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The Role of Renin–Angiotensin– Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging. High Blood Press Cardiovasc Prev. 2018;25(2):137-145. doi:10.1007/s40292- 018-0252-5.

15. Bosch J, Lonn E, Pogue J, Arnold JMO, Dagenais GR, Yusuf S. Long‑term effects of Ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension. Circulation. 2005;112(9):1339-1346.

16. Kostis WJ, Thijs L, Richart T et al. Persistence of Mortality Reduction After the End of Randomized Therapy in Clinical Trials of Blood Pressure‑Lowering Medication. Hypertension. 2010;56:1060-1068.

17. Cífková R. Co přinášejí nové tabulky SCORE. [Rozhovor] Oficiální kongresové zpravodajství České kardiologické společnosti. Dostupné z WWW: https://cks22.ckstv.cz/

18. Lopez‑Gonzalez AA, Aguilo A, Frontera M, et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol. 2015 Mar;22(3):389-96.

19. Parati G et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension. Hypertension 2021;77:692–705

20. Wald S et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Ann. Int. Med. 2009 21. SPC – souhrn údajů o přípravku Lipertance, datum revize textu 22.7.2022, www.sukl.cz.